Fig. 2 NK Fc
RIIIa polymorphisms inXuencing cytotoxic activity on cetuximab-treated SCCHN TU167. a NK cells from individual donors expressing either F/F, V/F or V/V alleles were tested for cytotoxicity against TU167 in a standard 51 Cr-release assay. Before addition of eVector cells, TU167 target cells were pretreated with media alone (Wlled diamond), human IgG1 isotype control at 10 g/ml (Wlled square) or cetuximab 10 g/ml (Wlled triangle). Data are representative of independent experiments performed in triplicates, with error bars indicating SEM. b NK cells from 17 donors expressing either F/F, V/F or V/V alleles were tested for cytotoxicity against the TU167 SCCHN cell line using a standard 51 Cr-release assay. Before addition of eVector cells TU167 targets were pretreated with media alone, human IgG1 isotype control at 10 g/ml, or cetuximab at 10 g/ml. Donors with either Fc RIIIa V/V or Fc RIIIa V/F demonstrated signiWcantly higher % cytotoxicity compared to Fc RIIIa F/F, when incubated with 10 g/mL cetuximab (P = 0.04 and 0.004, respectively). Shown is the mean of n = 7, 7 and 3 for FF, VF and VV, respectively, with error bars representing SEM 
